In this study, we identified P2X7R as an upstream of NLRP3, and that suppression of the P2X7R-NLRP3 axis could attenuate EAP development, which may be a therapeutic approach for chronic prostatitis treatment. The gene discussed is NLRP3; the disease is chronic prostatitis.